

We are the only PARKINSON'S FOUNDATION CENTER OF EXCELLENCE in the region with comprehensive care including doctors specialized in the diagnostics, treatment, research, and education of Parkinson's disease. We have a large multi-disciplinary team including healthcare professionals specialized in Parkinson's disease in the areas of psychology, speech, physical therapy, occupational therapy, dietetics, social work, pharmacy, neuropsychology, and neurosurgery, including a large deep brain stimulation program.

Parkinson's Disease Symposium - Over 600 In Attendance!



The PD Symposium was a great success! In addition to excellent lectures, there were displays with educational materials, treatment options, assistive devices, programs and classes throughout the region, exercise, boxing, and research opportunities.

Picture: Dr. Vibhash Sharma, KU, Dr. Kelvin Au, KU, Dr. Kelly Lyons, KU, Dr. Rajesh Pahwa, KU, Dr. Stuart Isaacson, Boca Raton, Dr. Swarna Mandali, KU, Dr. Andrea Lee, KU (coming soon)



RAJESH PAHWA, MD

Laverne and Joyce Rider
Professor of Neurology
Director, Parkinson's
Disease and Movement
Disorder Center



KELLY LYONS, PhD

Research Professor
of Neurology
Director, Research and
Education, Parkinson's Disease
and Movement Disorder Center

TREMOR CORNER

ET Studies Ongoing!

JZP385 – Moderate to severe arm/ hand tremor. Cannot be taking ET medications

PRAX-944 – ET for at least 3 years with at least moderate arm/hand tremor. Not taking primidone.

SAGE-324 – ET for at least 3 years with at least moderate arm/hand tremor. Cannot be taking other medications for ET.

To participate in a research study or for more information, email pdetcenter@kumc.edu or call 913-588-7159.

Join the 2022 Virtual Education Conference
October 29, 2022 presented by the IETF
REGISTER HERE!

Visit www.essentialtremor.org for more information
about programs and information for persons with ET!

CLINICAL STUDIES RECRUITING

We have multiple ongoing and upcoming studies for PD. We are currently enrolling for the following studies:

- Newly diagnosed PD patients - Possible disease slowing**
 - UCB0599** - PD patients diagnosed < 2 yrs, never taken PD medications
 - K0706** – PD patients diagnosed < 3 years and not taking any PD medications
 - CVL-751** – PD patients diagnosed for < 3 years and taking no PD medications except for an MAO-B inhibitor
- Stable PD patients**
 - PADOVA** – PD patients taking only an MAO-B inhibitor OR levodopa diagnosed within the last 3 years
 - STEM-PD** - Moderate non-motor symptoms affecting daily activities
- PD patients experiencing OFF time (poor control of symptoms) during waking hours**
 - AMDC-009-103** - PD patients experiencing OFF time, on demand inhalation therapy for OFF episodes
 - CVL-751** – PD patients with at least 2.5 hours of OFF time per day
- PD patients experiencing troublesome dyskinesia (wiggling movements from levodopa)**
 - BK-JM-201** – PD patients with at least 1.5 hours of troublesome dyskinesia daily and not taking or willing to stop amantadine
- PD Generation Mapping the Future of Parkinson's Disease**– Testing for 7 genes that have been shown to increase the risk of developing Parkinson's disease. Anyone diagnosed with Parkinson's disease in our region can participate.
- The Parkinson's Progression Markers Initiative (PPMI)**
 - Parkinson's Disease cohort (PD diagnosed within the last 2 years, not on or expected to need meds for 6 months)
 - Prodromal cohort (1st degree relative with PD, REM sleep behavior disorder (RBD), or known genetic variants; 60+ years of age),
 - Healthy Controls (30+ years of age).

If you are interested or have patients who are interested in learning more about any of these research studies, please contact PDETCenter@kumc.edu

PD SYMPOSIUM RESEARCH HIGHLIGHT

Dr. Isaacson, Director, PD Center of Boca Raton, discussed the importance of genetic research and future treatment options. As the cause of PD is still unknown, a better understanding of the role of genes in developing PD is critical. It is commonly believed that PD is the result of an interaction between genes and environment. Several genes have been identified as risk factors for PD, but to date they have been found in only 15-20% of PD patients. Genetic testing studies are ongoing to test 1000's of persons with PD to determine the prevalence of the known genes and identify new genes associated with PD. This will allow for the development of new treatments targeting specific genes related to PD.

He also highlighted the large number of PD studies ongoing and the importance of participating in research. There are several studies targeting the protein alpha-synuclein in an attempt to slow PD progression, studies of improved and new treatment options to control motor and non-motor symptoms of PD, and studies to more accurately diagnose PD. The development of new treatments is a long and costly process, and many studies fail due to an inability to find people who are willing to participate. You can become a part of advancing PD research at KU! For more information email PDETCenter@kumc.edu or call 913-588-7159.

Helen Gold 5K/10K, FOR PARKINSON'S CANCELLED

Visit our website: KUMC.EDU/PARKINSON for PD information